In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across workflows, and FDA's approval of a gene therapy for a rare childhood syndrome.
News|Podcasts|June 26, 2026
ACT Brief: Bridging Site-Sponsor Data Gaps, Major Study Retraction, and TNBC First-Line Approval
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine integrating site and sponsor data systems, a high-profile trial retraction over integrity concerns, and a new first-line breast cancer treatment.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- Following DIA 2026, Jonathan Andrus, co-CEO of CRIO,
described how central eSource integration can bridge fragmentation between site systems and sponsor oversight. His model combines protocol-driven templates with site-level flexibility, reducing administrative burden while enabling better patient focus. - Nature Medicine retracted a Phase III lung cancer
study after identifying documentation discrepancies, mid-trial protocol changes on ClinicalTrials.gov, and unusual data patterns inconsistent with typical Phase III datasets. The LungTIME-C01 trial claimed dramatic survival benefits from morning immunochemotherapy administration but lacked audit confidence in its integrity. - The FDA
approved Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, both as monotherapy and combined with pembrolizumab. ASCENT-03 showed 38% reduction in disease progression versus chemotherapy, marking the first new backbone therapy for this disease in over two decades.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
In today's ACT Brief, we examine what families with rare epilepsy teach about trial feasibility, how preclinical CRO partnerships are evolving beyond transactional services, and why cortisol dysregulation limits GLP-1 effectiveness in diabetes.
In today's ACT Brief, we examine how shifting patient engagement to endpoint selection improves trial data quality, why execution infrastructure must precede AI deployment, and addressing missing baseline data in real-world oncology research.
In today's ACT Brief, we examine why seizure reduction misses what families want from epilepsy trials, how lab coordination requires connecting data to intent, and why healthcare needs orchestration rather than more tools.
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
Trending on Applied Clinical Trials Online
1
Four Years After Disrupting Clinical Trial Diversity at DPHARM, Acclinate Is Back to Disrupt the Data Behind It
2
How a Platform Approach Can Scale AI’s Impact in Life Sciences
3
DPHARM 2026: Why Making Technology Easier Isn't Enough for Sites
4
DPHARM 2026: What the Patient-Site Relationship Needs Most Right Now
5